Clinical Trials Browser

Phase 2/3 × INDUSTRY × naptumomab estafenatox × Clear all

NCT00420888 2015-07-22

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Phase 2/3 Completed

Carcinoma, Renal Cell